-
1
-
-
0036583164
-
Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes
-
Ahren B, Simonsson E, Larsson H. Landin-Olsson M, Torgeirsson H, Jansson PA, Sandqvist M, Bavenholm P, Efendic S, Eriksson JW, Dickinson S and Holmes D. Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care 2002; 25: 869-875.
-
(2002)
Diabetes Care
, vol.25
, pp. 869-875
-
-
Ahren, B.1
Simonsson, E.2
Larsson, H.3
Landin-Olsson, M.4
Torgeirsson, H.5
Jansson, P.A.6
Sandqvist, M.7
Bavenholm, P.8
Efendic, S.9
Eriksson, J.W.10
Dickinson, S.11
Holmes, D.12
-
2
-
-
9444285818
-
Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes
-
Ahren B, Gomis R, Standl E, Mills D and Schweizer A. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 2004a; 27: 2874-2880.
-
(2004)
Diabetes Care
, vol.27
, pp. 2874-2880
-
-
Ahren, B.1
Gomis, R.2
Standl, E.3
Mills, D.4
Schweizer, A.5
-
3
-
-
2442482515
-
Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes
-
Ahren B, Landin-Olsson M, Jansson PA, Svensson M, Holmes D and Schweizer A. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. The Journal of Clinical Endocrinology and Metabolism 2004b; 89: 2078-2084.
-
(2004)
The Journal of Clinical Endocrinology and Metabolism
, vol.89
, pp. 2078-2084
-
-
Ahren, B.1
Landin-Olsson, M.2
Jansson, P.A.3
Svensson, M.4
Holmes, D.5
Schweizer, A.6
-
4
-
-
23044487247
-
Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year
-
Ahren B, Pacini G, Foley JE and Schweizer A. Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. Diabetes Care 2005; 28: 1936-1940.
-
(2005)
Diabetes Care
, vol.28
, pp. 1936-1940
-
-
Ahren, B.1
Pacini, G.2
Foley, J.E.3
Schweizer, A.4
-
5
-
-
12244281855
-
Circulation and degradation of GIP and GLP-1
-
Deacon CF. Circulation and degradation of GIP and GLP-1. Hormone and Metabolic Research 2004; 36: 761-765.
-
(2004)
Hormone and Metabolic Research
, vol.36
, pp. 761-765
-
-
Deacon, C.F.1
-
6
-
-
0346753557
-
A strategy of plasma protein quantitation by selective reaction monitoring of an intact protein
-
Ji QC, Rodila R, Gage EM and El-Shourbagy TA. A strategy of plasma protein quantitation by selective reaction monitoring of an intact protein. Analytical Chemistry 2003; 75: 7008-7014.
-
(2003)
Analytical Chemistry
, vol.75
, pp. 7008-7014
-
-
Ji, Q.C.1
Rodila, R.2
Gage, E.M.3
El-Shourbagy, T.A.4
-
7
-
-
0029118049
-
Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV
-
Kieffer TJ, McIntosh CH and Pederson RA. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 1995; 136: 3585-3596.
-
(1995)
Endocrinology
, vol.136
, pp. 3585-3596
-
-
Kieffer, T.J.1
McIntosh, C.H.2
Pederson, R.A.3
-
8
-
-
3843121153
-
Glucagon-like peptide-1: The basis of a new class of treatment for type 2 diabetes
-
Knudsen LB. Glucagon-like peptide-1: the basis of a new class of treatment for type 2 diabetes. Journal of Medicinal Chemistry 2004; 47: 4128-4134.
-
(2004)
Journal of Medicinal Chemistry
, vol.47
, pp. 4128-4134
-
-
Knudsen, L.B.1
-
9
-
-
85164048340
-
-
Madar DJ, Kopecka H, Pireh D, Yong H, Pei Z, Li X, Wiedeman PE, Djuric SW, Von Geldern TW, Fickes MG, Bhagavatula L, McDermott T, Wittenberger S, Richards SJ, Longenecker KL, Stewart KD, Lubben TH, Ballaron SJ, Stashko MA, Long MA, Wells H, Zinker BA, Mika AK, Beno DW, Kempf-Grote AJ, Polakowski J, Segreti J, Reinhart GA, Fryer RM, Sham HL and Trevillyan JM. Discovery of 2-(4-((2-(2S,5R)-2-Cyano-5-ethynyl-1- pyrrolidinyl)-2-oxoethylamino)-4-methyl-1-piperidinyl)-4- pyridinecarboxylic acid (ABT-279): a very potent, selective, e ffective, and well-tolerated inhibitor of dipeptidyl peptidase-IV, useful for the treatment of diabetes. Journal of Medicinal Chemistry 2006; 49: 6416-6420.
-
Madar DJ, Kopecka H, Pireh D, Yong H, Pei Z, Li X, Wiedeman PE, Djuric SW, Von Geldern TW, Fickes MG, Bhagavatula L, McDermott T, Wittenberger S, Richards SJ, Longenecker KL, Stewart KD, Lubben TH, Ballaron SJ, Stashko MA, Long MA, Wells H, Zinker BA, Mika AK, Beno DW, Kempf-Grote AJ, Polakowski J, Segreti J, Reinhart GA, Fryer RM, Sham HL and Trevillyan JM. Discovery of 2-(4-((2-(2S,5R)-2-Cyano-5-ethynyl-1- pyrrolidinyl)-2-oxoethylamino)-4-methyl-1-piperidinyl)-4- pyridinecarboxylic acid (ABT-279): a very potent, selective, e ffective, and well-tolerated inhibitor of dipeptidyl peptidase-IV, useful for the treatment of diabetes. Journal of Medicinal Chemistry 2006; 49: 6416-6420.
-
-
-
-
10
-
-
0027215348
-
Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum
-
Mentlein R, Gallwitz B and Schmidt WE. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. European Journal of Biochemistry 1993; 214: 829-835.
-
(1993)
European Journal of Biochemistry
, vol.214
, pp. 829-835
-
-
Mentlein, R.1
Gallwitz, B.2
Schmidt, W.E.3
-
11
-
-
0035857020
-
New drug targets for type 2 diabetes and the metabolic syndrome
-
Moller DE. New drug targets for type 2 diabetes and the metabolic syndrome. Nature 2001; 414: 821-827.
-
(2001)
Nature
, vol.414
, pp. 821-827
-
-
Moller, D.E.1
-
12
-
-
0026659679
-
Glucagon-like peptide-1, a new hormone of the entero-insular axis
-
Orskov C. Glucagon-like peptide-1, a new hormone of the entero-insular axis. Diabetologia 1992: 35: 701-711.
-
(1992)
Diabetologia
, vol.35
, pp. 701-711
-
-
Orskov, C.1
-
13
-
-
0031033531
-
Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM
-
Rachman J, Barrow BA, Levy JC and Turner RC. Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM. Diabetologia 1997; 40: 205-211.
-
(1997)
Diabetologia
, vol.40
, pp. 205-211
-
-
Rachman, J.1
Barrow, B.A.2
Levy, J.C.3
Turner, R.C.4
-
15
-
-
33845565220
-
Developing multiple high-throughput GLP methods for an investigational drug candidate in various matrices within a 96-well plate
-
Zhang J, Kim EJ, Ji QC and El-Shourbagy TA. Developing multiple high-throughput GLP methods for an investigational drug candidate in various matrices within a 96-well plate. Rapid Communications in Mass Spectrometry 2006; 20: 3755-3760.
-
(2006)
Rapid Communications in Mass Spectrometry
, vol.20
, pp. 3755-3760
-
-
Zhang, J.1
Kim, E.J.2
Ji, Q.C.3
El-Shourbagy, T.A.4
|